Company / Accounts Receivable
ARS Pharmaceuticals, Inc. Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$25.3M
FY2025
5-year range
$0 / $25.3M
FY2023-FY2025
Trend
+210.1%
vs FY2024
Sector context
#88 of 113
Health Care
What the data says
ARS Pharmaceuticals, Inc.'s accounts receivable of $25M is lower than 78% of companies in the Health Care sector (FY2025). Improved from $0 to $25M over the past 2 years.
Based on SEC 10-K filings.
$25M in FY2025.
Improved from $0 to $25M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 113This company $25.3M Sector average $1.1B
▼
-97.8% below sector average
Key checks
Key Insights
- In FY2025, accounts receivable increased 210.1% year-over-year.
- Ranks #88 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.3M | +210.1% |
| FY2024 | $8.2M | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026